Binding reactions: epigenetic switches, signal transduction and cancer  by Ptashne, Mark
Current Biology Vol 19 No 6
R234
the mechanisms by which buds arise 
and differentiate. Recent work has 
shown that in most species each 
reiterated sequence — rather than 
each zooid — arises as a single bud 
within the growth zone and then 
gives rise to multiple zooids through 
subdivision. Siphonophores also 
have complex symmetry properties 
that deviate from the simple radial 
symmetry usually associated with 
cnidarians. The colonies can even be 
directionally asymmetric, with some 
structures consistently displaced to 
one side or the other just as our own 
heart is usually displaced towards the 
left sides of our body.
What is it like to work with 
siphonophores? Siphonophores 
are a joy to study. When reading 
about some aspect of their biology, 
one is just as likely to reach for a 
mid-19th century monograph or 
a paper that came out in the last 
year. So many questions are wide 
open — some requiring the same tools 
and approaches as the naturalists 
of the Age of Exploration, others 
necessitating modern high- throughput 
sequencing technologies. When 
collecting deep- sea specimens with 
submersibles, many of the acquired 
siphonophores are often undescribed 
species. Rarely do biologists have 
such an excellent opportunity to pull 
together such disparate tools in the 
pursuit of core conceptual questions. 
In addition, one siphonophore species 
has been cultivated through its full 
life cycle in the lab, while others can 
routinely be collected in the field. 
Expressed sequence tag (EST) libraries 
are currently under development 
that will enable analyses of colony 
development at the molecular level.
Where can I find out more?
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Simple binding interactions lie at the heart of disparate biological functions. 
Multiple negative and positive ‘add-ons’, often with small individual effects, 
make elementary systems that work, work better. Cancer illustrates various of 
these fundamental processes gone awry.
EssayMolecular biology continues to 
explode with new facts and details 
along with the occasional surprise. 
There is, I believe, an unexpected 
bonus: a few basic principles underlie 
many complex processes — signal 
transduction, gene expression, 
the maintenance or destruction of 
gene products, the construction of 
epigenetic switches, and so on. In 
some human diseases — cancer, 
for example — these processes go 
awry, and a conceptualization of 
the underlying strategies helps us 
understand how that can happen. 
Here I emphasize nature’s reiterated 
use of the simplest of reactions: 
binding.
By binding, I mean the non-covalent 
interactions of macromolecules: 
proteins with other proteins, DNA, 
RNA, or membranes; of RNA 
with DNA, and so on. The typical 
interaction I refer to is reversible 
under physiological conditions, and 
its essential function is apposition, 
bringing one macromolecule in 
contact with another. In this essay 
I discuss a few examples of how 
binding reactions are deployed to 
different ends. Molecular details 
differ, but similar general strategies 
are found at work in these systems. 
The essentials are illustrated by the 
workings of an epigenetic switch in 
bacteria, my starting example.
An epigenetic switch: lessons 
from lambda 
The bacteriophage lambda switch 
ensures that when one set of genes 
(those for lysogenic growth) are 
on, another set (the genes for lytic 
growth) are off, and vice versa. Once 
the repressor gene (cI) is switched on 
(Figure 1, left) and the lysogenic state 
established, that pattern of the gene 
expression is self-perpetuated for many bacterial divisions. The switch 
can be flipped by an environmental 
signal — such as UV light — but none 
of the operations of the switch entails 
a change in DNA sequence. Rather, 
the switch comprises a set of binding 
reactions involving two DNA-binding 
regulatory proteins (repressor and 
cro), the enzyme RNA polymerase and 
DNA. Here are some further salient 
points describing, or inferred from, 
the switch. These matters, as well as 
certain others discussed later in this 
article and not explicitly referenced, 
have been discussed previously [1,2].
• Epigenetics. The 
self- perpetuating (and hence 
epigenetic) character of the switch is 
not an inherent property of any of its 
components, but rather is a property 
of the system conferred by the pattern 
of binding reactions. There are two 
ways to make epigenetic switches, 
and lambda’s switch includes both: 
a double-negative loop, in which 
the product of one gene (repressor) 
turns off expression of the other 
gene (cro) and vice versa; and a 
positive feedback loop, in which 
repressor (despite its name) activates 
transcription of its own gene. The 
original name my colleagues and I 
gave to this switch — we called it 
a ‘genetic’ switch — is misleading 
because, as just mentioned, there is 
no change in DNA sequence involved 
[3]. Epigenetic switches comprising 
lambda-like components are found 
in many developmental pathways in 
eukaryotes.
• Cooperativity. The switch requires 
that proteins bind specifically to sites 
on DNA. For example, a lysogen 
repressor must bind to its designated 
sites in DNA and, more precisely, 
it must bind predominantly to two 
of three such sites as shown in 
Figure 1, on the left. This specificity 
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repressor dimers touch (bind) each 
other as shown, each thereby 
helping the other bind, and to bind 
specifically. All binding reactions 
of the sort discussed in this article 
face the specificity problem, and 
cooperativity is widely used to help 
solve the problem (see appendix one 
in [1]). I return below to a further role 
of cooperativity in the lambda switch.
• Concentration control. The 
individual DNA sites in Figure 1 differ 
only modestly in their affinities for 
repressor — about tenfold. And so 
site selectivity tends to be rather 
readily lost as the concentration of 
repressor increases. Not to worry: the 
switch has a ‘governor’ in the form 
of another binding reaction — as the 
repressor concentration increases 
it tends to turn off transcription of 
its own gene by binding to the third 
(lower affinity) site, as shown by the 
downward arrow in Figure 1, on the 
left. The binding reactions referred 
to in this article require that binding 
domains distinguish between related 
possible targets. These kinds of 
interactions risk losing specificity as 
concentrations increase.
• Activation of transcription – the 
imposition of specificity by 
recruitment. Lambda repressor 
works as an activator of transcription 
in another binding reaction: it 
simultaneously contacts DNA and RNA 
polymerase (as shown in Figure 1), 
thereby recruiting the polymerase to 
the adjacent promoter. Transcription 
of the gene is ‘activated’ — that is, 
the gene is transcribed at a higher 
level than it otherwise would be. The 
gene activated by repressor is the 
repressor-encoding cI gene itself and 
so, by this positive feedback loop, 
continuous production of repressor 
is ensured as these lysogenic cells 
divide. 
We say that polymerase has 
been given specificity — has been 
instructed to transcribe a particular 
gene, the cI gene — by this recruiting 
reaction. The effect is modest 
(increasing the level of transcription 
some 10–50-fold) and a potentially 
significant level of transcription will 
occur in the absence of the activator. 
When repressor is destroyed and 
lysogens induced, cro, the DNA-
binding protein produced early upon 
induction, suppresses this basal 
transcription as shown on the right in 
Figure 1.Cro
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Lysogen
λ repressor
Lytic growth
(repressor destroyed)
Induction
Cro
123
λCro
cIcI
RNA polymerase
Current Biology
Figure 1. The lambda epigenetic switch.
Two states of the switch are shown: on the left the repressor gene (cI) is transcribed but the Cro 
gene is not, and vice versa on the right. The scenario on the left is found in lambda lysogens, 
bacteria that carry an otherwise dormant phage lambda. Inactivation of repressor (induction) 
results in lytic growth of the phage, an early stage of which is shown on the right. Repressor 
and cro turn each other’s genes off by blocking binding of RNA polymerase to the other’s pro-
moter: repressor covers the Cro gene promoter when bound at sites 1 and 2 as shown on the 
left, and cro covers the repressor-gene promoter when bound at site 3, as shown on the right. 
Repressor bound at sites 1 and 2 activates transcription of its own gene (cI), as it represses 
transcription of Cro. Repressor maintains its concentration below a specified level by binding, 
at higher concentrations, to site 3 (as indicated by the downwards arrow), and turning itself off. 
All of these effects — auto-activation and repression by repressor, and the opposing effects 
of repressor and cro — are effected by simple binding reactions with suitably adjusted bind-
ing constants. The figure indicates that the switch can be flipped by a dose of UV light which 
results indirectly in cleavage of repressor. An additional set of interactions involving repressors 
bound here and at a site some 2000 base pairs away has been omitted.Many eukaryotic enzymes can, 
like bacterial RNA polymerase, 
work on any of a wide array of 
substrates (different genes in the 
case of RNA polymerase), and 
which is chosen, under any given 
set of conditions, is determined by 
recruitment, as in the example just 
discussed. These enzymes include, in 
addition to polymerases, proteases, 
ubiquitylators, RNA-splicing 
enzymes, kinases, phosphatases, 
transcriptional repressing complexes, 
nucleosome modifying enzymes, and 
so on. For example, an E2 ligase can 
add ubiquitin to many proteins, but 
the choice is dictated (for one class 
of E2s) by recruiters called F-box 
proteins. Each of these recruiters 
simultaneously binds a specific target 
protein and the enzymatic machinery, 
and thus imposes specificity on the 
enzyme. Ubiquitin is added and, in a 
further binding reaction, the modified 
protein interacts with a protease and 
is destroyed. 
Recruiting reactions typically face 
the problem described for activation 
of transcription: in the absence of the 
recruiter there can be an unwanted 
basal level of activity, and we will see 
a variety of strategies employed to 
depress that basal activity. 
• Squelching and self-squelching. 
Recruiting reactions are subject 
to two negative effects as the concentration of the recruiter 
increases. Squelching: an over-
expressed transcriptional activator, 
as it activates its target genes, will 
tend to depress transcription of 
other genes. The effect is attributed 
to competition by activators (the 
recruiters in this case) for binding 
common sites on the transcriptional 
machinery. The effect has been 
observed in transcription experiments 
performed with yeast and mammalian 
cells. Self-squelching: At very high 
expression levels, a transcriptional 
activator ceases to activate even its 
designated target genes. The result 
is explained as follows: successful 
recruitment requires that a single 
recruiter (a transcriptional activator 
in this case) simultaneously contacts 
the transcriptional machinery and 
a specific DNA binding site. At very 
high activator concentrations, the 
machinery and the DNA site will tend 
to be occupied by separate copies 
of the activator, and recruitment will 
be blocked. The effect has been 
observed in transcription experiments 
performed in yeast, and in proteolysis 
experiments in mammalian cells in 
which the concentration of an E3 
ligase (the recruiter in this case) 
was varied (Pengbo Zhou, personal 
communication).  
For any given case the extent of 
squelching and self-squelching will 
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of recruiters and targets and the 
affinities with which they bind 
each other. As a historical matter, 
the observation of squelching and 
self-squelching was one of the 
early indications that eukaryotic 
transcriptional activators work by 
recruitment. Another important kind 
of experiment in this regard is called 
a ‘by-pass’ experiment, as now 
outlined.
• By-pass experiments. A 
property of reactions facilitated by 
recruitment is that the recruiter can 
be dispensed with (‘by-passed’) if 
the target and enzyme are brought 
together in another fashion. For 
example, bacterial RNA polymerase 
constitutively transcribes a gene, at a 
high level, if fused to a DNA- binding 
domain that binds a site near the gene. 
(Presumably the DNA binding domain 
is pulled off its site as the polymerase 
moves along the gene, but this has 
not been explicitly demonstrated.) 
An analogous result obtains if a 
subunit of the eukaryotic transcription 
machinery is fused to a DNA-binding 
domain. In both of these examples 
the requirement for a transcriptional 
activator is obviated. Over-producing 
a target protein can suffice to drive a 
reaction in the absence of a recruiter. 
The price paid in such by-pass 
scenarios is that the ordinary control 
over the reaction — effected usually 
by production or modification of the 
recruiter — is lost. 
A by-pass experiment has 
shown that double-stranded RNA 
(dsRNA) works as a recruiter in the 
phenomenon called RNA interference 
(RNAi). In this experiment a 
‘silencing’ protein (a component of 
the RITS complex) was fused to an 
RNA- binding protein. The binding 
site for that protein was inserted into 
a transcribed yeast gene, and the 
fusion was found to trigger silencing 
of that gene. [4]. Thus the sole role 
of dsRNA in RNAi is to direct the 
silencing machinery to a specific 
sequence. 
• Add-ons. Sophisticated systems 
can be produced by the step-wise 
addition of one recruiting (or simple 
binding) reaction to another, each 
addition making the system work 
more efficiently. The lambda switch 
might have evolved in this fashion, 
a notion we infer from the fact that 
certain of its features can be singly 
eliminated by mutation without destroying its overall function. For 
example, elimination of the positive 
feedback loop (auto-activation 
of the cI gene), or of a negative 
feedback loop (auto- repression of 
the cI gene), creates a phage that 
can lysogenize, and these lysogens 
can be induced, but the processes 
are less efficient than those obtained 
with wild- type phage. And there is 
a layer of cooperativity of repressor 
binding in addition to that shown 
in Figure 1 — the four depicted 
repressor monomers interact with 
four more repressor monomers 
bound some 2000 base pairs away. 
This high degree of cooperativity 
contributes to the ‘switch-like’ 
(all- or- none) character of induction. 
Thus, three features — auto- activation 
and repression, and high 
cooperativity — are ‘add-ons’ that 
make a system that works, work better.
We find ‘add-ons’ working at a 
‘silent’ region of a yeast chromosome. 
Here dsRNA, continuously produced 
from the silenced region, works 
together with a set of specific DNA 
binding protein recruiters. Together 
they ensure continual recruitment of 
the proteins required for silencing. 
Eliminating any one of the recruiting 
elements renders the silencing less 
stable [5].
• A shorthand. For convenience 
we say ‘repressor turns off Cro’. 
This is of course a shorthand way of 
describing what actually happens: 
repressor and polymerase compete 
for binding to DNA. The higher the 
repressor concentration, the more 
frequently it will occupy its binding 
sites and the more completely it will 
exclude binding of RNA polymerase 
to the promoter of the cro gene. 
We often use shorthand — ‘turn 
on, turn off’, ‘bound, free’ — when 
describing binding reactions, but we 
are talking about matters of degree 
and graded effects. In eukaryotes 
specific DNA binding repressors work 
by recruiting repressing complexes 
and these repressing complexes work 
in graded opposition to the effects of 
transcriptional activators [6]. As noted 
in the preceding section, the imposition 
of ever more cooperativity can 
convert graded effects to something 
resembling ‘on-off’ switches.
An illustrative signal transduction 
pathway
Every step of the eukaryotic signal 
transduction pathway outlined in Figure 2, from signal to gene product, 
involves a binding reaction. The figure 
is a composite of steps found in 
different pathways (see figure legend) 
[7]. Two kinds of enzymes appear 
here. First, of course, there are the 
enzymes (enzymatic ‘machines’) 
that transcribe genes, splice RNAs, 
and translate mRNAs. Second, we 
encounter enzymes whose only role 
in signal transduction, so far as I 
know, is to make or break binding 
sites. These enzymes include kinases 
and guanine nucleotide exchange 
factors (GEFs). All of these enzymes 
have multiple possible substrates, 
and specificity — which substrate 
is chosen by each enzyme — is 
determined by binding/recruiting 
reactions.
Kinases
Three familiar kinds of kinases are 
involved in the pathway: two of 
these add phosphate to proteins, 
(to tyrosine residues, and to serine/
threonine residues), and the third 
adds phosphate to a membrane 
lipid constituent called phosphatidyl 
inositol bis-phosphate (PIP2). In 
each case the resulting modification 
presents a binding site recognized 
by one or another of the array 
of recognition modules found in 
eukaryotes [8,9]. For example, SH2 
domains bind phospho-tyrosine; 
14-3-3 domains bind phospho- serine/
threonine; and certain PH domains 
bind the modified membrane 
component PIP3. In some cases 
phosphorylation, rather than creating 
a binding site directly, does so 
indirectly. That is, phosphorylation 
can cause a conformational change in 
a kinase that increases its activity. But 
because kinases, ultimately, make or 
break binding sites, this consideration 
adds a wrinkle to, but not a 
reformulation of, our general rule.
As mentioned above, kinase 
specificity — which protein is picked 
to be phosphorylated — is itself often 
determined by binding reactions. 
The active sites of tyrosine kinases, 
for example, are notoriously similar, 
and specificity depends on binding 
reactions not involving the enzymes’ 
active sites. In some cases recruiters 
(‘adaptors’) are used; in others, 
residues on the kinase, separate 
from the active site, direct binding 
to specific targets; in still others, 
we have ‘scaffolds’ that bind one or 
more kinase molecules plus a specific 
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Figure 2. A representative eukaryotic signal transduction pathway. 
(A) The two-chain receptor spans the plasma membrane. Its two chains have been brought together by binding of the protein ligand, a growth 
factor. By virtue of this apposition, each attached kinase adds a phosphate to a tyrosine residue on the partner chain (pink dots). (B)The adaptor 
protein Grb2, which bears an SH2 domain, simultaneously binds the modified tyrosine and SOS, thereby recruiting the latter to the membrane 
and thus to Ras. (C) Ras, activated by SOS, recruits to the membrane a PI 3-kinase (purple). (D) The recruited kinase coverts PIP2 to PIP3. (E) 
PIP3 is bound by a PH domain attached to another kinase (yellow), positioning the latter so that it can be phoshorylated, and thereby activated, 
by the green kinase anchored in the membrane. (F) A further binding interaction, perhaps involving a scaffold, (not shown) promotes phospho-
rylation of a transcription factor, a modification that leads to its dimerization. (G) The dimer enters the nucleus (in a further binding reaction, not 
explicitly shown). (H) The protein dimer binds to DNA cooperatively with another protein dimer. (I) Activation of transcription is illustrated as a 
two-step process: the activator recruits a ‘nucleosome remodeler’ Swi/Snf (which removes nucleosomes from the promoter), and then it recruits 
the transcriptional machinery. The latter comprises multiple proteins, including RNA polymerase, and the third line depicts the polymerase 
transcribing the gene. A prior step might be involved: the activator might first recruit enzymes that facilitate recruitment of the nucleosome-
remover by creating binding sites on the nucleosomes. (J) The blue/purple protein bound to a specific site on the RNA is a “splicing regulator” 
that recruits the splicing machinery to effect proper splicing. The mRNA is transported out of the nucleus (another binding reaction, not shown) 
and (K) translated into protein. Steps A–K are found in one or another growth factor pathway [7]; steps F–H are found in the Stat pathway [11]; 
and the steps in (I) represent a case in yeast [13].substrate; and so on. In some cases, 
(not represented here), addition 
of phosphate can block a binding 
reaction that would otherwise occur. 
Apposition of kinases with proper 
targets is often intimately associated 
with an increase in enzymatic activity, 
a matter I return to below. 
GEFs
SOS is an enzyme (a GEF) that 
encourages the small GTP-binding 
protein Ras to exchange a GDP for a 
GTP and thereby assume an ‘active’ 
conformation. In that conformation 
it exposes a binding site for another 
protein. There are many different small G proteins, often present as 
domains attached to other protein 
domains and/or to a membrane. 
They form nearly identical overall 
structures when active, each 
displaying a different binding site. 
Because Ras, the small G protein 
in our example, is tethered to a 
membrane, exposure of its binding 
site fosters recruitment of its target(s) 
to the membrane. We will see that 
SOS itself is recruited to Ras by a 
binding reaction.
The steps of the pathway
The following points are detailed 
more fully in the Figure 2 legend. At certain points, recruited enzymes 
create binding sites: for example, 
kinases create protein–protein 
binding sites in (A) and (F); another 
kind of protein–protein interaction 
site is created by SOS in (B); another 
kinase creates a membrane-protein 
binding site in (D). Transcriptional 
activating proteins bind cooperatively 
to DNA in (H). In a two step 
recruiting process, an inhibitor is 
first removed from DNA, and then 
the transcriptional machinery is 
brought to the gene (I). Recruitment 
of the RNA splicing machinery to 
RNA is illustrated in (J); and, finally 
(K), the mRNA is translated into 
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the archetypical example of binding 
reactions determining specificity — in 
this case the loaded tRNAs bind 
specific triplets in the mRNA, and 
thereby present a specific array of 
amino acids for the translational 
machinery to work on. 
Here are some further comments 
on this signal transduction pathway 
in light of the principles we deduced 
from the lambda case.
• Inhibition of basal signaling. At 
several steps there is the inevitable 
problem of spontaneous binding and 
a low level of constitutive (basal) 
activation of the pathway. And so, as 
we had anticipated, various inhibitors 
suppress this basal signaling: some 
help keep the receptor chains apart in 
the absence of the ligand; others bind 
the receptor and cover the tyrosines 
in the chains that are subject to 
phosphorylation; still others block 
spontaneous dimerization of the 
transcriptional activators, and so on 
[10,11]. These inhibitors work with 
affinities such that their effects are 
overcome in the presence of the 
signal. 
The basal activities of 
kinases — which otherwise would 
tend to create binding sites 
spontaneously — are inhibited in 
various ways. As we have noted, 
phosphorylation of kinases is often 
required for their full enzymatic activity. 
That modification, under ordinary 
conditions, and absent a specific 
kinase-to-kinase binding interaction, 
should occur spontaneously only 
rarely. Kinases often bear self-
inhibitory domains whose effects 
are overcome by the presence of 
the proper substrate. For example, 
the tyrosine kinase Src (not shown 
in Figure 2) bears an SH2 domain 
that, by binding a phosphorylated 
tyrosine on another part of the kinase, 
holds the enzyme in an inactive state. 
And because the SH2 domain is 
buried, binding of the kinase to most 
phosphorylated targets is inhibited. 
But binding of the SH2 (probably 
working cooperatively with other 
binding domains — see the following 
section) to its preferred target apposes 
the enzyme with the proper substrate 
and relieves internal inhibition. Thus 
the kinase is active only when it should 
be. The cyclin-dependent kinases 
(Cdks) are also controlled so as to 
be active only when called upon to 
work: in this case each cyclin, which recruits a cdk to a specific set of 
targets, simultaneously binds to and 
induces a conformational change in 
the kinase that greatly increases its 
activity. Certain other kinases, working 
in tandem, respond synergistically 
to activating signals, and this feature 
would also tend to depress effects of 
basal level signaling [12]. 
The effects of kinases and GEFs 
tend to be erased by enzymes 
that catalyze the opposing 
reactions — phosphatases and 
GTPase-activating proteins (GAPs). 
These enzymes, sometimes working 
as recruited functions and sometimes 
as background functions, thus 
counter basal level production of 
binding sites that might otherwise 
occur. The importance of these 
competing reactions is illustrated 
by the fact that signal transduction 
pathways are spontaneously 
activated when cells are treated with 
a general phosphatase inhibitor. 
Basal level transcription in 
eukaryotes is suppressed by the 
wrapping of DNA into nucleosomes. 
As depicted in Figure 2, one of the 
earliest effects of a DNA-bound 
transcriptional activator in yeast is 
to recruit an enzyme that removes 
nucleosomes from the promoter 
region, thus clearing the way for 
recruitment, by the activator, of 
the transcription complex. This 
separate nucleosome-removal 
step is another ‘add-on’ — in its 
absence (in a mutant cell lacking 
the nucleosome-removing enzyme), 
recruitment of the transcriptional 
machinery suffices for activation, but 
the time required for full induction 
is longer. Evidently, in the absence 
of the nucleosome- removing step, 
the recruited machinery eventually 
out- competes nucleosomes for 
binding to the promoter. The delay 
caused by the absence of the 
nucleosome-removing enzyme is 
strikingly long, at least ten-fold (five 
hours versus 30 minutes for the wild 
type, roughly) [13], a matter I refer to 
in discussing artificial induction of 
stem cells near the end of this article.
• Specificity and cooperativity. 
In the lambda example, we noted 
the specificity problem faced by 
DNA-binding domains — they 
must distinguish not only between 
specific and non-specific sites, 
but also between stronger and 
weaker binding sites in DNA, a 
problem solved at least in part by cooperativity. We also noted that 
other kinds of binding reactions must 
solve similar problems. For example, 
like members of any given class of 
DNA-binding domains, SH2 domains 
all form similar overall structures, 
and yet they must distinguish 
one target from another — in this 
case one phosphorylated tyrosine 
from another. To some extent this 
selectivity is imposed by preferences 
for one or another of the few residues 
flanking the modified tyrosine 
residue. The preferences are weak, 
however, and it is likely that these 
domains usually find their proper 
targets using cooperativity. That is, 
one SH2 can work in conjunction with 
another SH2 on the same protein or 
in another associated component; or 
the SH2 domain might work together 
with a different protein-binding motif 
(an SH3 domain, for example); or with 
one that binds a membrane; and so 
on [9,14]. The typical representation 
of a signal transduction pathway 
(such as in Figure 2) ignores this likely 
complexity.
• By-pass effects. As suggested by 
our previous discussion of by- pass 
experiments, several steps in our 
pathway can be manipulated so 
as to eliminate the role of one or 
another recruiter that is ordinarily 
required. In each of these cases 
transcription of the target gene is 
elicited in the absence of the signal. 
Thus, for example, overproducing the 
receptor chain leads to spontaneous 
dimerization and triggering of the 
pathway; introducing a protein 
bearing SOS′ (a SOS derivative 
lacking an inhibitory domain) 
attached to a peptide sequence that 
anchors it in the membrane has a 
similar effect, as does overproducing 
SOS′; and, as already noted, a fusion 
protein bearing the appropriate 
DNA binding domain, attached to 
a component of the transcriptional 
machinery, activates transcription of 
the target gene. 
• The non-epigenetic nature of 
the pathway. Our signal transduction 
pathway, once activated, is not 
self-perpetuating. Once the supply 
of ligand is exhausted the pathway 
shuts down as (among other factors) 
the binding sites created by the 
enzymes are erased. To make the 
signal self-perpetuating we need add 
positive feedback. One way to do 
this, if the activated gene encodes 
a transcriptional activator, would be 
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that activator near the gene. Another 
would be for the signal to cause 
transcription of a gene the product 
of which, in one way or another, 
leads to overproduction of the 
receptor chain and its concomitant 
spontaneous dimerization. And so 
on. These imagined modifications 
show, once again, that epigenetic 
(self- perpetuating) effects are 
properties of systems, not of 
individual components.
Evolving new specificities 
and complexities 
Natural selection can readily survey, 
and select among, a wide array of 
signaling pathways with different 
specificities. Determinants of binding 
reactions are readily ‘swappable’ 
and have expanded into families 
of related binding domains. There 
are minimal stereo-specificity 
requirements for recruitment — a 
DNA-binding domain typically can be 
attached at either end of, or within, 
a transcriptional regulator; an SH2 
domain can similarly be placed at any 
of several places in a protein, and so 
on, all without loss of the designated 
function. The evolutionary path often 
emphasized in ‘evo-devo’ discussions 
invokes changes in ‘cis- regulatory’ 
sites in DNA. Thus, for example, 
the DNA- binding sites used in the 
example of Figure 2 could be put in 
front of any gene and, because most 
(perhaps all) transcriptional activators 
work on most genes, in that new 
configuration the new gene will be 
brought under control of the ligand 
used in the illustration. But the binding 
steps in the pathway provide many 
places where specificities — which 
genes are activated by which 
signals — are readily swapped and 
expanded. For example, any kinase 
bearing the recognition domains 
found on the yellow kinase in Figure 2 
(including a PH domain, which, like 
the other recognition modules we 
have discussed, is readily attached 
to proteins) will be recruited to the 
membrane by the modification shown 
in Figure 2. And so on. 
These systems lend themselves 
to constant improvement in the 
form of add-ons. Various inhibitory 
and facilitating binding reactions 
can be imposed on the system 
step-wise, each making the system 
work just a bit better. And where 
those add-ons must themselves be controlled we need new binding 
reactions — inhibitors of inhibitors and 
facilitators, and so on. A seemingly 
endless regress of binding reactions.
What can go wrong
Cancer
Cancer is said to be a disease of 
aberrant signaling. I have emphasized 
how binding/recruiting reactions can 
lie at the heart of signaling pathways. 
Indeed, as a tour of a modern cancer 
text [7] reveals, most ‘cancer-causing’ 
mutations involve components of 
binding reactions. These comprise 
a rather restricted set: recruiters, 
inhibitors, inhibitors of inhibitors, 
receptors, and enzymes that 
make/break binding sites. (Obvious 
exceptions include mutations that 
affect DNA repair processes, but 
these presumably cause mutations 
in genes such as those emphasized 
here; and mutations of certain 
receptors, such as Notch, that 
are activated by a process more 
elaborate than simple apposition of 
receptor chains). Members of the 
various categories listed here, when 
not deleted, are found to bear point 
mutations, to be overexpressed, 
and/or to be fused to heterologous 
domains. Here are a few well-known 
examples — many more can easily 
be found:
• Recruiters: transcription factors 
(P53, myc, E2F, each controlling 
expression of sets of genes); E3 
ligases (FBW7, an F-box protein that 
targets Myc and other transcripton 
factors; MDM2, which targets 
P53); Ras, in a mutant form that is 
constitutively ‘active’; and cyclins. 
• Receptors: Her2; EGF 
receptor; Ret.
• Inhibitors: Rb, which binds and 
blocks the activating function of 
E2F; P27, which binds and inhibits a 
Cdk–cyclin complex; Ids, which bind 
and prevent dimerization of a class of 
transcription factors.
• Inhibitors of inhibitors: Arf, which 
blocks binding of MDM2 to p53.
• Enzymes that make or break 
binding sites: kinases, sometimes 
associated with receptors (Kit), and 
sometimes not (Src); phosphatases 
(PTEN), and GEFs (Sos).
Binding reactions, and hence 
signaling pathways, are easily 
subverted, as shown by the behavior 
of certain viral proteins: the Large T 
antigen of SV40 virus binds Rb and thereby blocks Rb binding to E2F, and 
similarly binds and sequesters p53; 
EBNA-6, encoded by Epstein- Barr 
virus, binds and carries to the nucleus 
a protein that, in turn, binds Rb 
and thereby prevents its interaction 
with E2F [15]; the E6 protein of 
human papilloma virus recruits an 
E3 ligase to P53, thereby causing its 
destruction. And so on.
The identification of these and 
other ‘cancer causing’ genes 
encourages the ideas that small, 
discrete sets of mutant genes 
cause specific cancers, and that 
sequencing ‘parental’ (germline) DNA 
will reveal strong predispositions 
to specific cancers. These kinds 
of genomic analyses have thus 
far run into problems. In a typical 
example of a germline mutation 
that has a major effect on disease 
susceptibility , breast cancer, only a 
small proportion of cases (~10%) is 
strongly associated with a common 
inherited defect (in this case a mutant 
BRCA gene). In other cases familiar 
mutations, not inherited, are found 
in a significant fraction of specific 
tumors, but these mutations are also 
found in other kinds of tumors. And, it 
is reported that many mutations with 
small effects contribute to solid tumor 
formation. Might our depiction of a 
signal transduction pathway — as 
a series of binding reactions and 
reactions that create/break binding 
sites — give hints as to a possible 
explanation for these findings?
Consider the finding of so many 
mutations with inferred small effects 
[16]. Our signaling pathway, just as 
the lambda switch, includes various 
add-ons that make the pathway work 
better, but are not essential — these 
include, for example, the various 
inhibitors, alluded to above, that 
dampen spontaneous signaling. 
Wouldn’t one expect that these 
systems would work with 
ever- decreasing efficiencies as such 
add-ons were lost? And how readily 
would mutations causing such 
changes be recognized? How would 
one recognize, for example, the single 
amino acid change in a target protein 
that decreased its affinity for an E3, 
and thereby caused the protein to be 
present at a concentration a few- fold 
higher than the optimal level? At 
some point the accumulation of 
such effects could be disastrous.
Many cancer mutations are 
‘by- passers’, changes that obviate 
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For example, a kinase (Abl), fused 
to another protein, has unfortunate 
effects that vary depending on just 
which recruiting domains have been 
included in the fusion; a receptor 
chain (Ret) fused to a dimerization 
domain, spontaneously dimerizes 
and triggers the pathway; a kinase 
(PI 3-kinase) bearing a mutation 
that increases its affinity for the 
membrane by-passes a signal in a 
different way. And so on.
Many mutations result in the 
over-expression of one or another 
component of signaling pathways. 
One effect of such overproduction, 
even of a wild-type protein, 
would be to allow by-pass of 
an ordinarily- required signal. 
For example, an over-produced 
transcription factor will tend to bind 
its sites on DNA absent its usual 
partners (with which it ordinarily 
binds cooperatively), and even to 
bind sites it ordinarily never sees. 
Similar considerations would apply 
to all the binding partners that use 
cooperativity in finding their partners. 
And, to a degree that will depend 
on the strengths of the relevant 
binding sites, and on the degree of 
overproduction, any overproduced 
recruiter — transcription factor, E3, 
and so on — would be expected to 
cause non-specific inhibition of the 
targeted enzyme (squelching), and 
at higher concentrations, to block 
its own action (self-squelching), as 
discussed above. Wild-type cells 
have feedback mechanisms that 
discourage  continuing overproduction 
of a protein — the lambda governor 
is an example, as is the action of E3 
ligases. The accumulated loss of 
such feedbacks can render otherwise 
harmless changes dangerous.
The kinases present a particularly 
worrisome problem. The similarities 
in the active sites of tyrosine kinases 
mentioned above explain why it has 
been so hard to find specific tyrosine 
kinase inhibitors. (Gleevac, the drug 
that with some selectivity inhibits 
the bcr-abl kinase, evidently does 
so by trapping the enzyme in an 
inactive conformation, a conformation 
evidently not adopted by most 
other kinases.) Kinases depend, for 
specificity, upon binding reactions 
involving residues not associated 
with their active sites. Src, discussed 
above, is a telling example. Mutant 
Src was one of the earliest cancer genes discovered — and it was found 
to be over-expressed in a mutant 
form that had lost the self-inhibitory 
feature described above. Such a 
berserk kinase would be expected to 
have non-specific effects, creating 
binding sites where it shouldn’t. 
We noted above that cancer is a 
disease of aberrant signaling. But it 
is also the result of an experiment 
in evolution — the cancer cell is 
selected to grow absent certain 
signals and restraints. Systems in 
which specificity is determined in 
large part by the kinds of binding 
reactions discussed here lend 
themselves not only to the unwanted 
activation or inhibition of this or 
that signaling pathway, but also to 
the production of ‘new’ pathways 
that allow for abnormal growth of 
cells. There may be many ways 
to interchange parts to effect any 
specified end. 
Other diseases and processes
Perhaps it is also worth keeping 
these considerations in mind when 
analysing certain human diseases 
other than cancer. The genetic bases 
of autism and schizophrenia, for 
example, have so far proved difficult 
to pin down, with many different 
mutations in different combinations 
evidently contributing to the 
outcomes [17]. Perhaps matters 
will clarify and just a few specific 
pathways will turn out to be affected, 
and in ways we can understand. An 
unfortunate alternative would be 
that there are many different ways 
to elicit similar phenotypes, perhaps 
by the accumulation of mutations 
with small effects. At the opposite 
end of the spectrum we have certain 
other neurological diseases, each 
of which is caused primarily by a 
defect in a specific gene. Each of 
these cases involves a single binding 
protein, and in each case elimination 
of the protein has an effect at least 
superficially similar to even a two- fold 
over-expression of that protein: Rett 
syndrome (the protein is MeCP2, 
which binds methylated sites on 
DNA); fragile X syndrome (the protein 
binds RNA); and Angleman syndrome 
(the protein is a transcription factor) 
[18]. Might one or another of the 
dosage dependent effects we have 
discussed be relevant here?
Concerns about levels of 
transcription factors — specific 
DNA binding recruiters, in our terminology — arise in experiments in 
which differentiated cells are induced 
to form cells with stem-cell- like 
qualities. As originally described, 
this required the introduction of four 
such recruiters into differentiated 
cells, and more recent experiments 
indicate that too high a level of a 
recruiter can be as detrimental as its 
absence [19]. And the conversions 
are maddeningly slow, taking many 
days. But perhaps this too should not 
be surprising — recall our example 
[13] showing that simple induction 
of a single gene can be drastically 
delayed by the absence of a single 
factor. It is not hard to imagine that 
the differentiated cells respond 
slowly to the introduced recruiters 
because they are lacking one or more 
co- factors with which these recruiters 
ordinarily work more quickly. 
Conclusion
Recruiting reactions have been used 
by natural selection to produce a 
wide array of complex biological 
processes. Just as Darwin required, 
these processes can be diversified 
and improved upon by step-wise 
modifications. The very simplicity 
of the nature of the underlying 
interactions accounts for much of 
the complexity we find in cells: rather 
than neat Ferrari-like engines that are 
switched on and off, we have binding 
reactions between macromolecules 
that must be encouraged to 
proceed in response to signals, 
and prevented from occurring 
spontaneously. These systems 
require, at least, cooperativity, control 
of concentrations, and inhibitory 
effects that come in many guises. 
As the lambda example shows, 
these requirements can be met, and 
a sophisticated epigenetic switch 
produced, with binding reactions 
involving just two regulatory proteins 
and RNA polymerase. With the 
appearance of enzymes that  
make/break binding sites — including 
kinases, phosphatases, GEFs, 
ubiquitylating enzymes — the 
possible scenarios are vastly 
multiplied. (For a recent probing of 
how a series of binding reactions 
control, in eukaryotes, the DNA 
damage response, and ultimately 
progression through the cell cycle, 
see [20].)
Natural selection was not restricted 
to considering, and tinkering with, 
the messy world of recruiting 
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A sober moderation stands sure, no violent 
extremities endure. 
Charles Aleyn, ‘The Battaile of Crescey’ (1633)
One of the key features of animal 
development is the precise control 
of gene expression. This can range 
from regulating rapid changes of 
transcript levels in both space and 
time to maintaining concentrations 
at a constant level for extended 
developmental periods. This latter 
case includes stabilizing or locking- in 
the transcriptional pattern of 
differentiated cell types. Much of the 
complexity of transcriptional control 
involves the interplay of transcriptional 
activators and repressors on 
cis- regulatory modules that reside 
close to target genes: these consist of 
transcription factor binding sites with 
specific arrangements and affinities 
that integrate the contributions 
from combinations of transcription 
factors, leading to transcriptional 
output. Many developmentally 
important transcription factors 
control sizeable gene batteries. 
Consequently, it is important that 
their levels are tightly controlled so 
that target genes can dependably 
perform their specific developmental 
functions. Numerous examples exist 
in which developmental defects are 
observed when levels of important 
transcription factors are only mildly 
altered by genetic lesions. These 
include the thoracic phenotype 
caused by a Drosophila Ultrabithorax 
(Ubx) homeotic mutation in just a 
single copy (haploinsufficiency), and 
human developmental disorders of the 
skeleton (cleidocranial dysplasia) and 
heart (Holt-Oram syndrome) caused 
by haploinsufficient reductions in 
the RUNX2 and TBX5 transcription 
factors, respectively.
There are a number of biochemical 
rationales for why levels of 
transcription factors are maintained 
within defined limits during 
Primerreactions. Intermediary metabolism, for example, is run by enzymatic 
machines that are revved up and 
down by allosteric responses to the 
binding of small molecules. And in 
bacteria we know of one set of genes 
that is not regulated by recruitment: 
the inactive promoters bear a 
special form of tightly-bound RNA 
polymerase, and the activator uses 
energy in the form of ATP to turn on 
transcription. In this system the basal 
level of transcription is vanishingly 
low, and so no repressor is required 
(or found). But as we encounter ever 
more complex organisms (and leave 
intermediary metabolism essentially 
unchanged) we find increasing 
roles played by the kinds of binding 
reactions discussed here. According 
to the following line of argument, this 
should not be surprising.
In The Origin of Species Darwin 
was, paradoxical as it might at 
first seem, looking at the simplest 
task evolution undertook — the 
elaboration of plants and animals. 
Unlike the evolution of bacteria that 
grow in disparate environments, 
the ‘recent’ evolution of these 
complex organisms required few 
new enzymatic activities — we 
have essentially the same set of 
such activities as do flies and other 
animals and plants. It’s as though 
once evolution had produced the 
enzymes found in eukaryotic cells, 
including those that make/break 
binding sites, it was easy to quickly 
deploy these enzymes, using 
recruiting reactions — specificity 
determinants — to different ends. 
Development of higher organisms 
is made possible by elaborate 
programs of intercellular signaling, 
and the signals are usually in the form 
of proteins or other macromolecules. 
The reiterated use of binding 
reactions to give meaning to these 
signals, as we have seen, comes 
with unavoidable dangers. Things 
can go awry in many ways, and, 
unfortunately, it can be hard to 
decipher what has gone wrong in 
any given case, and even harder to 
fix it. It would be easier if we had 
been intelligently designed and were 
made of neat machines. Like Ferrari 
engines.
Acknowledgements
I thank for helpful discussion Robert 
Benezra, Helen Blau, Nicolas Buchler, 
Jerry Coyne, Alex Gann, Shiv Grewal, Alan Hall, Oliver Hobert, Ross Levine, Danesh 
Moazed, Santosh Narayan, Ken Offit, Tony 
Pawson, John Petrini, Bruce Stillman, 
Vidya Prabhu, Bert Vogelstein, and Andrew 
L. Wolfe.
References
 1.  Ptashne, M. (2004). A Genetic Switch (Third 
Edition): Phage Lambda Revisited. (Cold 
Spring Harbor, New York: Cold Spring Harbor 
Laboratory Press.)
 2.  Ptashne, M. and Gann, A. (2002). Genes and 
Signals. (Cold Spring Harbor, New York: Cold 
Spring Harbor Laboratory Press.)
 3.  Ptashne, M. (2007). On the use of the word 
‘epigenetic’. Curr. Biol. 17, R233–R236.
 4.  Buhler, M., Verdel, A., and Moazed, D. (2006). 
Tethering RITS to a nascent transcript initiates 
RNAi- and heterochromatin-dependent gene 
silencing. Cell 125, 873–886.
 5.  Jia, S., Noma, K., and Grewal, S.I. (2004). 
RNAi-independent heterochromatin nucleation 
by the stress-activated ATF/CREB family 
proteins. Science 304, 1971–1976.
 6.  Gertz, J., Siggia E.D., Cohen, B.A. (2009). 
Analysis of combinatorial cis-regulation in 
synthetic and genomic promoters. Nature 457, 
215–218.
 7.  Weinberg, R.A. (2006). Biology of Cancer. 
(Oxford UK, Taylor & Francis Group Ltd.)
 8.   Pawson, T., and Nash, P. ( 2003). Assembly of 
cell regulatory systems through interaction 
domains. Science 300, 445–452.
 9.  Yaffe, M.B. (2002). Phosphotyrosine-binding 
domains in signal transduction. Nat. Rev. Mol. 
Cell Biol. 3, 1771–1786.
 10.  Massagué, J., Seoane, J., and Wotton, D. 
(2005). Smad transcription factors. Genes 
Dev. 23, 2783–2810. 
 11.  Mertens. C., and Darnell, J.E. Jr. (2007). 
JAK- STAT signaling. Cell 131, 612.
 12.  Ferrell, J.E. Jr. (1997). How responses get 
more switch-like as you move down a protein 
kinase cascade. Trends Biochem. Sci. 8, 
288–289.
 13.  Bryant, G.O., Prabhu, V., Floer, M., Wang, 
X., Spagna, D., Schreiber, D., and Ptashne, 
M. (2008). Activator control of nucleosome 
occupancy in activation and repression of 
transcription. PLoS Biol. 12, 2928–2939.
 14.  Jones, R.B., Gordus, A., Krall, J.A., and 
MacBeath, G. (2006). A quantitative protein 
interaction network for the ErbB receptors 
using protein microarrays. Nature 439, 
168–174. 
 15.  Kashuba, E., Yurchenko, M., Yenamandra, 
S.P., Snopok, B., Isaguliants, M., Szekely, L., 
and Klein, G. (2008). EBV-encoded EBNA-6 
binds and targets MRS18-2 to the nucleus, 
resulting in the disruption of pRb-E2F1 
complexes. Proc. Natl. Acad. Sci. USA 105, 
5489–5494. 
 16.  Beerenwinkel, N., Antal, T., Dingli, D., 
Traulsen, A., Kinzler, K.W., Velculescu, V.E., 
Vogelstein, B., and Nowak, M.A. (2007). 
Genetic progression and the waiting time to 
cancer. PLoS Comput. Biol. 11, e225.
 17.  Burmeister, M., McInnis, M.G., and Zöllner, S. 
(2008). Psychiatric genetics: progress amid 
controversy. Nat. Rev. Genet. 7, 527–540.
 18.  Ramocki, M.B., and Zoghbi, H.Y. (2008). 
Failure of neuronal homeostasis results 
in common neuropsychiatric phenotypes. 
Nature 455, 912–918.
 19.  Eminli, S., Utikal, J., Arnold, K., Jaenisch, R., 
and Hochedlinger, K. (2008). Reprogramming 
of neural progenitor cells into induced 
pluripotent stem cells in the absence of 
exogenous Sox2 expression. Stem Cells 10, 
2467–2474.
 20.  Usui, T., Foster, S.S., and Petrini, JH. (2009). 
Maintenance of the DNA-damage checkpoint 
requires DNA-damage-induced mediator 
protein oligomerization. Mol. Cell 33, 147–159.
Sloan Kettering Institute, Memorial Sloan 
Kettering Cancer Center, 1275 York Avenue, 
Box 595, New York, NY 10021, USA.  
E-mail: m-ptashne@mskcc.org
